167 related articles for article (PubMed ID: 32664931)
1. Providing reproductive health services for women who inject drugs: a pilot program.
Owens L; Gilmore K; Terplan M; Prager S; Micks E
Harm Reduct J; 2020 Jul; 17(1):47. PubMed ID: 32664931
[TBL] [Abstract][Full Text] [Related]
2. Barriers to hepatitis C treatment among secondary needle and syringe program clients and opportunities to intervene.
Gunn J; McNally S; Ryan J; Layton C; Bryant M; Walker S; O'Mahony C; Pedrana A
Int J Drug Policy; 2021 Oct; 96():103387. PubMed ID: 34330571
[TBL] [Abstract][Full Text] [Related]
3. "No-one just does drugs during business hours!": evaluation of a 24/7 primary needle and syringe program in St Kilda, Australia.
Walker S; Curtis M; Kirwan A; Thatcher R; Dietze P
Harm Reduct J; 2024 Feb; 21(1):51. PubMed ID: 38402389
[TBL] [Abstract][Full Text] [Related]
4. Trust and people who inject drugs: The perspectives of clients and staff of Needle Syringe Programs.
Treloar C; Rance J; Yates K; Mao L
Int J Drug Policy; 2016 Jan; 27():138-45. PubMed ID: 26394538
[TBL] [Abstract][Full Text] [Related]
5. Barriers and facilitators of access to HIV, harm reduction and sexual and reproductive health services by women who inject drugs: role of community-based outreach and drop-in centers.
Ayon S; Ndimbii J; Jeneby F; Abdulrahman T; Mlewa O; Wang B; Ragi A; Mburu G
AIDS Care; 2018 Apr; 30(4):480-487. PubMed ID: 29067855
[TBL] [Abstract][Full Text] [Related]
6. Developing integrated community-based HIV prevention, harm reduction, and sexual and reproductive health services for women who inject drugs.
Ayon S; Jeneby F; Hamid F; Badhrus A; Abdulrahman T; Mburu G
Reprod Health; 2019 May; 16(Suppl 1):59. PubMed ID: 31138238
[TBL] [Abstract][Full Text] [Related]
7. Scoping out the literature on mobile needle and syringe programs-review of service delivery and client characteristics, operation, utilization, referrals, and impact.
Strike C; Miskovic M
Harm Reduct J; 2018 Feb; 15(1):6. PubMed ID: 29422042
[TBL] [Abstract][Full Text] [Related]
8. Perceived discrimination and injecting risk among people who inject drugs attending Needle and Syringe Programmes in Sydney, Australia.
Wilson H; Brener L; Mao L; Treloar C
Drug Alcohol Depend; 2014 Nov; 144():274-8. PubMed ID: 25236889
[TBL] [Abstract][Full Text] [Related]
9. Healthcare utilisation and disclosure of injecting drug use among clients of Australia's needle and syringe programs.
Islam MM; Topp L; Iversen J; Day C; Conigrave KM; Maher L
Aust N Z J Public Health; 2013 Apr; 37(2):148-54. PubMed ID: 23551473
[TBL] [Abstract][Full Text] [Related]
10. Barriers to Healthcare for People Who Inject Drugs: A Survey at a Syringe Exchange Program.
Miller-Lloyd L; Landry J; Macmadu A; Allard I; Waxman M
Subst Use Misuse; 2020; 55(6):896-899. PubMed ID: 31902293
[No Abstract] [Full Text] [Related]
11. Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study.
Williams B; Howell J; Doyle J; Thompson AJ; Draper B; Layton C; Latham N; Bramwell F; Membrey D; Mcpherson M; Roney J; Stoové M; Hellard ME; Pedrana A
Int J Drug Policy; 2019 Oct; 72():91-98. PubMed ID: 31129023
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of pharmacy-based needle/syringe exchange programme for people who inject drugs: a systematic review and meta-analysis.
Sawangjit R; Khan TM; Chaiyakunapruk N
Addiction; 2017 Feb; 112(2):236-247. PubMed ID: 27566970
[TBL] [Abstract][Full Text] [Related]
13. Community attitudes towards harm reduction services and a newly established needle and syringe automatic dispensing machine in an inner-city area of Sydney, Australia.
White B; Haber PS; Day CA
Int J Drug Policy; 2016 Jan; 27():121-6. PubMed ID: 26118798
[TBL] [Abstract][Full Text] [Related]
14. Analysis of four syringe dispensing machine point-of-access data 2017-2020 in Melbourne, Australia: machine utilisation and client demographics.
Kerr P; Cossar RD; Livingston M; Jacka D; Dietze P; O'Keefe D
Harm Reduct J; 2022 Dec; 19(1):144. PubMed ID: 36544124
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of needle and syringe programs in Tajikistan distributing low dead space needles.
Zule WA; Latypov A; Otiashvili D; Bangel S; Bobashev GV
Harm Reduct J; 2018 Aug; 15(1):44. PubMed ID: 30170604
[TBL] [Abstract][Full Text] [Related]
16. A qualitative study trialling the acceptability of new hepatitis C prevention messages for people who inject drugs: symbiotic messages, pleasure and conditional interpretations.
Treloar C; Newland J; Maher L
Harm Reduct J; 2015 Mar; 12():5. PubMed ID: 25884357
[TBL] [Abstract][Full Text] [Related]
17. Toward a human-centered use of technology: a stakeholder analysis of harm reduction and CBO staff.
Aronson ID; Bennett AS; Freeman R
Harm Reduct J; 2020 Oct; 17(1):77. PubMed ID: 33076911
[TBL] [Abstract][Full Text] [Related]
18. Access and utilisation of reproductive, maternal, neonatal and child health services among women who inject drugs in coastal Kenya: Findings from a qualitative study.
Ndimbii J; Ayon S; Abdulrahman T; Mahinda S; Jeneby F; Armstrong G; Mburu G
Sex Reprod Healthc; 2018 Dec; 18():48-55. PubMed ID: 30420087
[TBL] [Abstract][Full Text] [Related]
19. Assessing Syringe Exchange Program Access among Persons Who Inject Drugs (PWID) in the District of Columbia.
Allen ST; Ruiz MS; Jones J
J Urban Health; 2016 Feb; 93(1):131-40. PubMed ID: 26786782
[TBL] [Abstract][Full Text] [Related]
20. Performance and image enhancing drug injectors' access to needle syringe programs: Responding to a public policy dilemma.
van Beek I; Chronister KJ
Int J Drug Policy; 2015 Sep; 26(9):868-74. PubMed ID: 26118797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
